Predictive value of serum dihomo-γ-linolenic acid level and estimated Δ-5 desaturase activity in patients with hepatic steatosis

Obesity Research and Clinical Practice

Volumn 11, Issue 1, 2017, Pages 34-43

  Matsuda, Morihiro ^a   Kawamoto, Toshiharu ^a   Tamura, Ritsu ^a  

^a NATIONAL HOSPITAL ORGANIZATION KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER   (Japan)

Author keywords

Dihomo linolenic acid; Hepatic steatosis; Insulin resistance; Obesity; 5 desaturase

Indexed keywords

ACYL COENZYME A DESATURASE 1; ALPHA GLUCOSIDASE INHIBITOR; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIHOMO GAMMA LINOLENIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOCOSAHEXAENOIC ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOREACTIVE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL; ACYL COENZYME A DESATURASE; BIOLOGICAL MARKER; DELTA-5 FATTY ACID DESATURASE;

ABDOMINAL RADIOGRAPHY; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHY SCANNER; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAPERITONEAL FAT; LIPID LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; INTRAABDOMINAL FAT; LIPID METABOLISM; LIVER; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; VERY ELDERLY;

8,11,14-EICOSATRIENOIC ACID; AGED; AGED, 80 AND OVER; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FATTY ACID DESATURASES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIVER; MALE; METABOLIC DISEASES; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; ROC CURVE;

EID: 84959480893     PISSN: 1871403X     EISSN: 18780318     Source Type: Journal    
DOI: 10.1016/j.orcp.2016.02.004     Document Type: Article

References (40)

1. [1] Shimabukuro, M., Kozuka, C., Taira, S., Yabiku, K., Dagvasumberel, M., Ishida, M., et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Investig 60 (2013), 1–14.
2. [2] Despres, J.P., Body fat distribution and risk of cardiovascular disease: an update. Circulation 126 (2012), 1301–1313.
3. [3] Shimomura, I., Matsuda, M., Hammer, R.E., Bashmakov, Y., Brown, M.S., Goldstein, J.L., Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6 (2000), 77–86.
4. [4] Utzschneider, K.M., Kahn, S.E., Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91 (2006), 4753–4761.
5. [5] Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
6. [6] Liu, J., Fox, C.S., Hickson, D., Bidulescu, A., Carr, J.J., Taylor, H.A., Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 31 (2011), 2715–2722.
7. [7] Kim, L.J., Nalls, M.A., Eiriksdottir, G., Sigurdsson, S., Launer, L.J., Koster, A., et al. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity 19 (2011), 1265–1271.
8. [8] Speliotes, E.K., Massaro, J.M., Hoffmann, U., Vasan, R.S., Meigs, J.B., Sahani, D.V., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 51 (2010), 1979–1987.
9. [9] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig 115 (2005), 1343–1351.
10. [10] Wolfram, G., Dietary fatty acids and coronary heart disease. Eur J Med Res 8 (2003), 321–324.
11. [11] He, K., Song, Y., Daviglus, M.L., Liu, K., Van Horn, L., Dyer, A.R., et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 109 (2004), 2705–2711.
12. [12] Satoh, N., Shimatsu, A., Kotani, K., Sakane, N., Yamada, K., Suganami, T., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 30 (2007), 144–146.
13. [13] Capanni, M., Calella, F., Biagini, M.R., Genise, S., Raimondi, L., Bedogni, G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23 (2006), 1143–1151.
14. [14] Patterson, E., Wall, R., Fitzgerald, G.F., Ross, R.P., Stanton, C., Health implications of high dietary omega-6 polyunsaturated fatty acids. J Nutr Metab, 2012, 2012, 539426.
15. [15] Fan, Y.Y., Chapkin, R.S., Importance of dietary gamma-linolenic acid in human health and nutrition. J Nutr 128 (1998), 1411–1414.
16. [16] Johnson, M.M., Swan, D.D., Surette, M.E., Stegner, J., Chilton, T., Fonteh, A.N., et al. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr 127 (1997), 1435–1444.
17. [17] Brenner, R.R., Hormonal modulation of delta6 and delta5 desaturases: case of diabetes. Prostaglandins Leukot Essent Fatty Acids 68 (2003), 151–162.
18. [18] Wang, Y., Botolin, D., Xu, J., Christian, B., Mitchell, E., Jayaprakasam, B., et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res 47 (2006), 2028–2041.
19. [19] Warensjo, E., Rosell, M., Hellenius, M.L., Vessby, B., De Faire, U., Riserus, U., Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. Lipids Health Dis, 8, 2009, 37.
20. [20] Vessby, B., Gustafsson, I.B., Tengblad, S., Boberg, M., Andersson, A., Desaturation and elongation of fatty acids and insulin action. Ann N Y Acad Sci 967 (2002), 183–195.
21. [21] Imamura, S., Morioka, T., Yamazaki, Y., Numaguchi, R., Urata, H., Motoyama, K., et al. Plasma polyunsaturated fatty acid profile and delta-5 desaturase activity are altered in patients with type 2 diabetes. Metabolism 63 (2014), 1432–1438.
22. [22] Fox, C.S., Massaro, J.M., Hoffmann, U., Pou, K.M., Maurovich-Horvat, P., Liu, C.Y., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116 (2007), 39–48.
23. [23] Maurovich-Horvat, P., Massaro, J., Fox, C.S., Moselewski, F., O'Donnell, C.J., Hoffmann, U., Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography. Int J Obes 31 (2007), 500–506.
24. [24] Kelley, D.E., McKolanis, T.M., Hegazi, R.A., Kuller, L.H., Kalhan, S.C., Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285 (2003), E906–E916.
25. [25] Ricci, C., Longo, R., Gioulis, E., Bosco, M., Pollesello, P., Masutti, F., et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 27 (1997), 108–113.
26. [26] Longo, R., Ricci, C., Masutti, F., Vidimari, R., Croce, L.S., Bercich, L., et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Investig Radiol 28 (1993), 297–302.
27. [27] DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988), 837–845.
28. [28] Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Yoshikawa, T., Hasty, A.H., et al. Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. J Lipid Res 43 (2002), 107–114.
29. [29] Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J.D., Brown, M.S., Goldstein, J.L., Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96 (1999), 13656–13661.
30. [30] Shimomura, I., Bashmakov, Y., Horton, J.D., Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274 (1999), 30028–30032.
31. [31] Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
32. [32] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
33. [33] Aguilar, M., Bhuket, T., Torres, S., Liu, B., Wong, R.J., Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313 (2015), 1973–1974.
34. [34] Rubin, D., Laposata, M., Regulation of agonist-induced prostaglandin E1 versus prostaglandin E2 production. A mass analysis. J Biol Chem 266 (1991), 23618–23623.
35. [35] Fan, Y.Y., Ramos, K.S., Chapkin, R.S., Dietary gamma-linolenic acid suppresses aortic smooth muscle cell proliferation and modifies atherosclerotic lesions in apolipoprotein E knockout mice. J Nutr 131 (2001), 1675–1681.
36. [36] Kawashima, H., Tateishi, N., Shiraishi, A., Teraoka, N., Tanaka, T., Tanaka, A., et al. Oral administration of dihomo-gamma-linolenic acid prevents development of atopic dermatitis in NC/Nga mice. Lipids 43 (2008), 37–43.
37. [37] Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993), 87–91.
38. [38] Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig 112 (2003), 1796–1808.
39. [39] Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig 114 (2004), 1752–1761.
40. [40] Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., Garg, R., Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005), 1448–1454.